Platinum-Based Chemotherapy-Induced Peripheral Neuropathy
Overview and Clinical Characteristics
Platinum-based chemotherapy, particularly oxaliplatin and cisplatin, causes a dose-dependent sensory peripheral neuropathy characterized by symmetric, distal, length-dependent "glove and stocking" distribution with predominantly sensory rather than motor symptoms. 1 This neuropathy affects approximately 38% of patients receiving platinum-containing regimens and can persist lifelong in 15-40% of patients after treatment completion. 2
Key Features of Platinum-Induced Neuropathy:
- Sensory axonal damage with reduced amplitude of sensory nerve action potentials on nerve conduction studies 1
- Oxaliplatin-specific acute syndrome: Cold-triggered paresthesias and muscle cramping that occur within hours to days of infusion 1
- Chronic cumulative neuropathy: Develops with repeated dosing and may continue to worsen even after chemotherapy cessation (a phenomenon called "coasting") 3
- Risk factors include: Diabetes, older age, higher cumulative doses, and longer treatment duration 2, 1
First-Line Treatment: Duloxetine
The American Society of Clinical Oncology recommends duloxetine as the only evidence-based first-line treatment for painful platinum-induced peripheral neuropathy, with particularly strong efficacy for oxaliplatin-induced neuropathy compared to taxane-induced neuropathy. 1, 4
Dosing Protocol:
- Start at 30 mg once daily for the first week 4, 5
- Increase to 60 mg once daily for ongoing treatment after the first week 4, 5
- Maximum dose is 60 mg daily; higher doses (120 mg) show no additional benefit and increase adverse effects 1
- Evidence level: Level I, Grade B 4
Clinical Evidence:
- In the pivotal trial, duloxetine showed 59% pain reduction versus 38% with placebo in 231 patients 6
- Exploratory subgroup analysis suggests duloxetine works better for oxaliplatin-induced neuropathy than paclitaxel-induced neuropathy 1
- Benefits include improvement in quality of life beyond pain relief 6
- Some patients experience pain decrease as early as week 1 5
Important Caveat:
When discontinuing duloxetine, taper slowly rather than stopping abruptly to avoid withdrawal symptoms (mental confusion, dizziness, nausea). 7
Second-Line Pharmacological Options
When duloxetine is ineffective, contraindicated, or not tolerated, consider the following alternatives in order:
Pregabalin or Gabapentin:
- Pregabalin: Start at 75 mg twice daily, increase to 150 mg twice daily after 1-2 weeks, maximum 300 mg twice daily 6
- Requires at least 2 weeks at adequate dosage before evaluating efficacy 6
- Evidence level: Level II, Grade C for CIPN specifically 4
- Caution: Can cause cognitive side effects, particularly problematic in elderly patients 6
- Note: A randomized trial of pregabalin for preventing oxaliplatin neuropathy was negative, but it may still have treatment benefit 7
Tricyclic Antidepressants (Nortriptyline):
- Target maximum dose of 100 mg/day 4
- Based on efficacy in other neuropathic pain conditions rather than CIPN-specific trials 1
- Major limitation: Can cause significant toxicity, especially in elderly patients (anticholinergic effects, cardiac conduction abnormalities, orthostatic hypotension) 1
Venlafaxine:
- Evidence level: Level II, Grade C 4
- Shown effectiveness in a small randomized trial 4
- Important note: Venlafaxine failed as a preventative agent for oxaliplatin neuropathy in larger trials 7
Topical Therapies
Compounded Baclofen/Amitriptyline/Ketamine Gel:
- Formulation: Baclofen 10 mg, amitriptyline HCL 40 mg, ketamine 20 mg 1, 4
- Showed improvement on CIPN-20 scores, especially the motor subscale, after 4 weeks 4
- Evidence level: Level II, Grade C 4
- Major limitation: Not commercially available; must be manufactured by a compounding pharmacy, and long-term safety has not been established 1
Menthol Cream (1%):
- Apply twice daily to affected areas and corresponding spinal dermatomal regions 4
- Improvement in pain scores after 4-6 weeks 6, 4
- Evidence level: Level III, Grade B 4
Capsaicin 8% Patches:
- Established efficacy for other neuropathic pain forms 6, 4
- Effects can last up to 90 days 6, 4
- Evidence level: Level I, Grade C for general neuropathic pain; Level III, Grade C for CIPN 4
- Particularly useful for localized pain areas if duloxetine and pregabalin fail 6
Topical Amitriptyline/Ketamine (4%/2%):
- Do not use: A large randomized placebo-controlled trial of 462 patients showed no effect on 6-week CIPN scores 7
Salvage Options: Opioids
Opioids should only be used as a last resort when all other treatments have failed, due to risks of addiction and potential worsening of symptoms. 6, 4
- Tramadol 200-400 mg in divided doses: Has dual mechanism (opioid + SNRI) and established efficacy for other neuropathic pain forms 6, 4
- Strong opioids: Use the smallest effective dose; may relieve neuropathic pain but carry significant risks 4
Non-Pharmacological Approaches
Exercise Therapy:
- Home-based muscle strengthening and balance exercises may provide benefit with significant reduction in neuropathic pain scores 4
- Should be recommended before and during chemotherapy for potential overall benefit 8
- Limitation: Larger studies are needed to confirm efficacy 4
Acupuncture:
- Two randomized trials show conflicting results 7
- Insufficient evidence for routine recommendation outside clinical trials 4
- May be tried based on patient preference and availability, given low risk profile 8
Physical Therapy:
- Can help address symptoms, particularly for balance issues and fall prevention in elderly patients 2, 8
- Limitation: Can be limited by cost, time commitment, and patient motivation 8
Scrambler Therapy:
- One phase II trial showed twice as many patients had ≥50% improvement compared to TENS (transcutaneous electrical nerve stimulation) 7
- Another trial showed no benefit over sham treatment 7
- Evidence is mixed; further research needed 7
Critical Agents to AVOID
For Treatment:
- Acetyl-L-carnitine: Should be avoided as it may worsen neuropathy over time 4
- NSAIDs and glucocorticoids: Have no supporting data for CIPN treatment 4
- Vitamin B12: Inferior to duloxetine 4
For Prevention:
No agents are recommended for preventing platinum-induced neuropathy. 1, 4 Specifically avoid:
- Calcium/magnesium infusions: Lack sufficient evidence and have concerns about reducing chemotherapy efficacy 4
- Venlafaxine: Failed in prevention trials despite initial promise 7
- Gabapentin/pregabalin: Negative trials for prevention 7
- Amifostine, glutathione, vitamin E, acetyl-L-carnitine: Not recommended 1
Monitoring and Long-Term Management
Clinical Assessment:
- Use self-reporting questionnaires dedicated to neuropathy: CIPN subscale of the EORTC QOL Questionnaire or Module NTX of the FACT questionnaire 2
- Regularly assess for comorbidities that may worsen symptoms (diabetes, vitamin deficiencies) 2
- Monitor for fall risk, particularly in elderly patients with sensory neuropathy 2
Supportive Care Measures:
- Physiotherapy and physical activity 2
- Referral to podiatrists for foot care 2
- Patient education on adequate footwear to prevent injuries 2
- Support in daily activities as needed 2
- Vitamin B supplementation can be discussed, though evidence is limited 2
Specialist Referral:
- Refer to neurologist if neuropathy induces chronic pain requiring specialized medication management 2
- Consider referral for nerve conduction studies if diagnosis is uncertain or symptoms are atypical 1
Chemotherapy Dose Modification
If intolerable CIPN symptoms develop during active treatment, chemotherapy doses may need to be reduced or treatment discontinued to prevent permanent nerve damage. 8, 3 This is a critical decision that must balance cancer treatment efficacy against quality of life and the risk of irreversible neuropathy, as CIPN can persist lifelong and significantly impact daily functioning. 2, 1